For the development of new drugs and the advancement of new cell therapies, pharmaceutical companies have recurred to cytotoxicity assays as a quick way to assess the viability of cell lines in response to an external stimulus.
The ongoing pursuit of novel anti-cancer therapeutics must consider the potential for off-target effects on the immune system.
Syngeneic tumor models and human immune cell-engrafted mice are two of the popular preclinical tools in immuno-oncology studies.
Nexcelom Bioscience, a leading provider of cell counting and characterization products for the life science industry, announced the launch of the revolutionary high throughput, high-speed automated cell counter – Cellaca™ MX.
Directly image and count calcein AM-labeled target cells in a 96-well plate using Celigo image cytometer. Concurrent imaging and analysis in 8 minutes.
By directly imaging and counting every cell in a well over a course of a drug treatment, the Celigo can perform the cytotoxicity assays in a label-free format.
